COMPARISON OF MYO-INOSITOL ALONE VERSUS IN COMBINATION WITH CLOMIPHENE CITRATE FOR MANAGEMENT OF FEMALES PRESENTING WITH POLYCYSTIC OVARIAN SYNDROME

Main Article Content

Dr Rabia Younis
Dr Azhar Abbas
Dr Masooma Kalsoom

Keywords

Ovulation, myoinositol, clomiphene citrate, polycystic ovarian syndrome.

Abstract

Objectives: To compare the frequency of ovulation with myo-inositol alone versus in combination with clomiphene citrate for management of females presenting with polycystic ovarian syndrome.


Materials and Methods:  In this RCT study, we enrolled a total of 500 females. Then females were randomly divided into two groups by using the lottery method. In group A, females were given 2g of myoinositol before breakfast and in group B, females were given 2g of myoinositol plus clomiphene citrate 50mg tablet before breakfast for 12 weeks. Females were followed up for 12 weeks. Then females underwent color Doppler ultrasonography for assessment of ovulation. If follicle of size ≥21mm ovulate from ovary on ultrasound, then ovulation was labeled. All this information was recorded through pre-designed proforma. The collected data was analyzed statistically by using SPSS version 21.


Results: In myoinositol group, the mean age of patients was 30.92±5.91years. In myoinositol plus clomiphene citrate group, the mean age of patients was 30.24±5.85years. After 4 weeks, ovulation was achieved in 39 (15.6%) patients with myoinositol and in 75 (30%) patients with myoinositol plus clomiphene citrate. After 8 weeks, ovulation was achieved in 119 (47.6%) patients with myoinositol and in 153 (61.2%) patients with myoinositol plus clomiphene citrate. After 12 weeks, ovulation was achieved in 154 (61.6%) patients with myoinositol and in 196


(78.4%) patients with myoinositol plus clomiphene citrate. The difference was significant (p<0.05).  


Conclusion: It was concluded that the combination of myoinositol and clomiphene citrate was more effective in ovulation in females with PCOS.

Abstract 183 | PDF Downloads 112

References

1. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. International journal of adolescent medicine and health. 2021;33(6):333-7.
2. Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian Journal of Medical Research. 2010;131(6):743-60.
3. Miazgowski T, Martopullo I, Widecka J, Miazgowski B, Brodowska A. National and regional trends in the prevalence of polycystic ovary syndrome since 1990 within Europe: the modeled estimates from the Global Burden of Disease Study 2016. Archives of Medical Science: AMS. 2021;17(2):343.
4. Hanif QA, Qamar S, Aslam P, Omar H, Mustafa N, Masood S. Association of vitamin D deficiency with polycystic ovarian syndrome. Pakistan Armed Forces Medical Journal. 2019;69(2):241-44.
5. Dumesic DA, Oberfield SE, StenerVictorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine reviews. 2015;36(5):487-525.
6. Cussons AJ, Stuckey BG, Walsh JP, Burke V, Norman RJ. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clinical endocrinology. 2005;62(3):289-95.
7. Franks S. Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):786-9.
8. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. The Journal of Clinical Endocrinology & Metabolism. 2006;91(11):4237-45.
9. Legro RS. Ovulation induction in polycystic ovary syndrome: current options. Best practice & research Clinical obstetrics & gynaecology. 2016;37:152-9.
10. Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, et al. Inositols: from established knowledge to novel approaches. International Journal of Molecular Sciences. 2021;22(19):10575.
11. Ribas Filho D, Nogueira-de-Almeida CA, Zotarelli-Filho IJ. Myo-inositol in polycystic ovary syndrome: a systematic review and positioning of its use. International Journal of Nutrology. 2022;15(2).
12. Boro T. Inositol and lipoic acid treatment in patients with polycystic ovary syndrome: University of Zagreb. School of Medicine; 2023.
13. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nature reviews Disease primers. 2016;2(1):1-18.
14. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. International journal of adolescent medicine and health. 2022;34(2):1-9.
15. Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani AD. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecological Endocrinology. 2015;31(2):131-5.
16. Gupta M, Singh D, Toppo M, Priya A, Sethia S, Gupta P. A cross sectional study of polycystic ovarian syndrome among young women in Bhopal, Central India. Int J Community Med Public Health. 2018;5(1):95-100.
17. Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome. Life sciences. 2019;236:116940.